Health and Healthcare
5864 Articles
Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs,…
Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back…
The $5.6 billion acquisition of Questcor Pharmaceuticals by specialty drugmaker Mallinckrodt started the week off with a big bang. But…
While the FDA has been far from a friend to MannKind over the past few years, the latest FDA panel…
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016…
Halozyme Therapeutics shares are getting pounded on Friday on news of a temporary halt of its Phase II trial enrollment…
ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering…
ThinkstockBoulder, Colo., ranked as the city least plagued by obesity, according to recent research. Among the 10 cities with the…
Amgen submitted an SEC Filing showing that, as of April 1, one of its subsidiaries and a GlaxoSmithKline subsidiary have…
New drug innovations are affecting the way that physicians treat such debilitating and deadly diseases as cancer. In a new…
Jon OggMost investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position…
In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples…
MannKind has a serious victory within its grasp. The company has struggled to get its Afrezza inhalable insulin to market…
ThinkstockMannKind Corp. (NASDAQ: MNKD)had been trading as though the stock was bracing for an U.S. Food and Drug Administration (FDA)…
ThinkstockThe first question anyone might ask if a stock falls from more than $9 to less than $2.50 is whether…
Our top personal finance-related articles today. Your wallet will thank you later.